AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Sunstar Suisse Sa Announces Its Acquisition from BMG Pharma S.p.A. of GelX® for the Treatment and Prevention of Oral Mucositis

February 25, 2019

ETOY, Switzerland--(BUSINESS WIRE)--Feb 25, 2019--Sunstar, a multi-national healthcare company based on oral care announces the acquisition from BMG Pharma S.p.A. of the innovative cancer supportive care product, GelX®. Through this acquisition Sunstar gains global distribution of this product line, expanding its position as a global leader in the development and commercialisation of oral healthcare products, mainly marketed under the GUM brand.

BMG Pharma S.p.A, an innovative specialty pharmaceutical company, will invest the proceeds from this transaction into the rapid development completion of a number of new patent protected products with topical, subcutaneous dermatology, osteoarthritis and oral care applications, which it will be able to offer to its network of global marketing partners.

Takeshi Kamigouchi, CEO of Sunstar Suisse SA, commented– “We are proud and excited to distribute the superior product GelX ® to make the difference in cancer patients’ oral conditions globally. Our purpose is to develop and provide products and services that promote mouth & body conceptto extend people’s healthy lifespan and improve their quality of life. GelX ® is truly expected as a product that plays a key role that demonstrates we are the purpose driven company.”

Marco Mastrodonato, CEO of BMG Pharma S.p.A., commented– “I have been partnering with Sunstar since 2002 with a win-win partnership in the oral care segment and at BMG are very proud to be the development and provider partner to a global oral care market leader. This is an important step for the company, bringing a strategic investment which represents a significant growth opportunity by allowing focus on the rapid completion of a number of products in our pipeline with unique propositions.

About Sunstar Suisse SA

Sunstar Suisse SA conducts business mainly in oral care products, such as toothbrushes, interdental brushes, toothpastes, dental rinses, and dental treatment related products for periodontal disease under the brands GUM®, BUTLER® and GUIDOR® throughout the world.

www.sunstar.com

About BMG Pharma S.p.A.

BMG Pharma S.p.A. is a specialty biotech pharmaceutical company with its head office in Milan, Italy, leveraging its proprietary technology platform in the hyaluronan and glycosaminoglycans to develop products that address unmet needs for patients in Dermatology Oral Care and Osteoarthritis BMG Pharma S.p.A. is dedicated to helping pharmaceutical companies in providing valuable and innovative products to patients, pharmacists and physicians.

www.bmgpharma.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20190225005057/en/

CONTACT: For press releases and other company information regarding Sunstar, visit:www.sunstar.com

and contact:Mr. Eiichi Shirakawa,

eiichi.shirakawa@ch.sunstar.com

Sunstar Suisse SA

Telephone number: +41 21 821 0500For press releases and other company information regarding BMG, visit: www.bmgpharma.com

and contact :Mrs. Loredana Galli, loredana.galli@bmgpharma.com

BMG Pharma S.p.A

Telephone number: +39 02 91321756

KEYWORD: UNITED STATES EUROPE NORTH AMERICA SWITZERLAND

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS HOSPITALS MEDICAL DEVICES ONCOLOGY PHARMACEUTICAL RADIOLOGY

SOURCE: BMG Pharma S.p.A.

Copyright Business Wire 2019.

PUB: 02/25/2019 09:00 AM/DISC: 02/25/2019 09:01 AM

http://www.businesswire.com/news/home/20190225005057/en